New Initiative at The Cancer Institute of New Jersey Aims to Advance Personalized Cancer Treatments through ‘Precision Medicine’
Research has shown that cancer is not one disease, but rather a collection of diseases. Each cancer sub-type boasts its own individual molecular makeup, which in many cases results in cancer growth and resistance to cancer-killing drugs. By further defining the molecular profile of various cancer subtypes, investigators hope to apply this information toward developing targeted therapies. Large scale efforts on the national and local levels – including those at CINJ – have been underway to collect correlating clinical and genomic data to use as a road map in determining diagnosis, prognosis and course of treatment. With CINJ's newly-established precision medicine initiative, specialized investigators will further integrate that information using state-of-the-art technology to better catalogue and expedite the flow of data from researcher to doctor to patient – and in turn back to the researcher.
Leading CINJ's initiative for precision medicine is Lorna Rodriguez, MD, PhD, who served as CINJ's chief of gynecologic oncology from 2000 until this year before being asked to take on this new role. Dr. Rodriguez has years of experience running her own investigator-initiated clinical trials including research on cancer metastasis, drug resistance and the CD44 cell surface receptor and the role it plays in ovarian cancer metastasis. She feels the impact of precision medicine both on patients and on the health/biomedical communities will be tremendous. "For the most part, clinicians are forced to rely on limited information to make treatment decisions, as there hasn’t been a mechanism to collect and catalogue such comprehensive data as tissue samples, patient history and treatment records to create the tumor profiles necessary for more personalized treatments," noted Rodriguez, who is also a professor of obstetrics, gynecology and reproductive sciences at UMDNJ-Robert Wood Johnson Medical School. "By compiling and further curating a collection of molecular and genetic data that will help drive new targeted therapies, we will be helping patients better manage their disease."
"This also will translate into cost savings, as no longer will doctors need to rely on hit-or-miss medicine," continued Rodriguez, who also performs gynecologic cancer surgeries and helps patients navigate chemotherapy options. "Currently, if one treatment is found to be ineffective, others are used -- and they come at a cost, both financially and in terms of lost time when the patient might have received effective treatment. With the prospects of precision medicine, we are moving closer to an era where we will be able to tailor cancer treatments to perfectly fit individualized patient profiles. This will also lead us to a better understanding in diagnosing disease and providing a prognosis."
The breast cancer drug trastuzumab is one example of how genomic information is helping to drive targeted cancer therapies. Study has shown that trastuzumab is effective for 20 percent of breast cancer patients whose cancer cells make too much of the HER2-positive protein. Because a genetic test can indicate whether a patient has the HER2-positive profile, doctors can better determine whether trastuzumab might be an effective treatment for them.
About The Cancer Institute of New Jersey
The Cancer Institute of New Jersey (www.cinj.org) is the state's first and only National Cancer Institute-designated Comprehensive Cancer Center dedicated to improving the detection, treatment and care of patients with cancer, and serving as an education resource for cancer prevention. CINJ’s physician-scientists engage in translational research, transforming their laboratory discoveries into clinical practice, quite literally bringing research to life. To make a tax-deductible gift to support CINJ, call 732-235-8614 or visit www.cinjfoundation.org. CINJ is a Center of Excellence of the University of Medicine and Dentistry of New Jersey-Robert Wood Johnson Medical School. Follow us on Facebook at www.facebook.com/TheCINJ.
The CINJ Network is comprised of hospitals throughout the state and provides the highest quality cancer care and rapid dissemination of important discoveries into the community. Flagship Hospital: Robert Wood Johnson University Hospital. System Partner: Meridian Health (Jersey Shore University Medical Center, Ocean Medical Center, Riverview Medical Center, Southern Ocean Medical Center, and Bayshore Community Hospital). Major Clinical Research Affiliate Hospitals: Carol G. Simon Cancer Center at Morristown Medical Center, Carol G. Simon Cancer Center at Overlook Medical Center, and Cooper University Hospital. Affiliate Hospitals: CentraState Healthcare System, JFK Medical Center, Robert Wood Johnson University Hospital Hamilton (CINJ Hamilton), Somerset Medical Center, The University Hospital/UMDNJ-New Jersey Medical School*, and University Medical Center at Princeton. *Academic Affiliate